Author(s): Le D, Uram J, Wang H, Bartlett BR, Kemberling H, et al.
Somatic mutations have the potential to encode “non-self” immunogenic antigens. We hypothesized that tumors with a large number of somatic mutations due to mismatch-repair defects may be susceptible to immune checkpoint blockade.
METHODSWe conducted a phase 2 study to evaluate the clinical activity of pembrolizumab, an anti–programmed death 1 immune checkpoint inhibitor, in 41 patients with progressive metastatic carcinoma with or without mismatch-repair deficiency. Pembrolizumab was administered intravenously at a dose of 10 mg per kilogram of body weight every 14 days in patients with mismatch repair–deficient colorectal cancers, patients with mismatch repair–proficient colorectal cancers, and patients with mismatch repair–deficient cancers that were not colorectal. The coprimary end points were the immune-related objective response rate and the 20-week immune-related progression-free survival rate.
Referred From: http://www.nejm.org/doi/10.1056/NEJMoa1500596
Author(s): Staehler MD, Kruse J, Haseke N, Stadler T, Roosen A, et al.
Author(s): Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, et al.
Author(s): Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, et al.
Author(s): Rini BI, Shaw V, Rosenberg, Kim ST, Chen I
Author(s): Choueiri TK, Fishman MN, Escudier B, McDermott DF, Drake CG, et al.
Author(s): Deguchi M, Shiina H, Igawa M, Kaneuchi M, Nakajima K, et al.
Author(s): Stoehr C, Burger M, Stoehr R, Bertz S, Ruemmele P, et al.
Author(s): Altavilla G, Fassan M, Busatto G, Orsolan M, Giacomelli L
Author(s): Leach FS, Koh M, Sharma K, McWilliams G, Talifero-Smith L, et al.
Author(s): Haugaard A, Pei Y, Fan Y, Cong Z
Author(s): Kelderman S, Schumacher TN, Kvistborg P
